Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Aim The guideline for coronary artery revascularization replaces the 2011 coronary artery
bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines …

always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …

These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …

5. Leczenie.............................................................. 1225 5.1. Farmakoterapia
niedokrwienia...................... 1225 5.1. 1. Ogólne leczenie objawowe................. 1225 5.1. 2 …